Titre : Inhibiteurs de la phospholipase A2

Inhibiteurs de la phospholipase A2 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Multicenter Studies as Topic
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Inhibiteurs de la phospholipase A2 : Questions médicales les plus fréquentes", "headline": "Inhibiteurs de la phospholipase A2 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Inhibiteurs de la phospholipase A2 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-03-18", "dateModified": "2025-03-13", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Inhibiteurs de la phospholipase A2" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Antienzymes", "url": "https://questionsmedicales.fr/mesh/D004791", "about": { "@type": "MedicalCondition", "name": "Antienzymes", "code": { "@type": "MedicalCode", "code": "D004791", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.389" } } }, "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de la phospholipase A2", "alternateName": "Phospholipase A2 Inhibitors", "code": { "@type": "MedicalCode", "code": "D064801", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "James A Shayman", "url": "https://questionsmedicales.fr/author/James%20A%20Shayman", "affiliation": { "@type": "Organization", "name": "Department of Internal Medicine, University of Michigan Medical School, University of Michigan, Ann Arbor, MI, USA. Electronic address: jshayman@umich.edu." } }, { "@type": "Person", "name": "Kathleen Fernandes Grego", "url": "https://questionsmedicales.fr/author/Kathleen%20Fernandes%20Grego", "affiliation": { "@type": "Organization", "name": "Laboratório de Herpetologia, Instituto Butantan, São Paulo, SP, Brazil." } }, { "@type": "Person", "name": "Akira Abe", "url": "https://questionsmedicales.fr/author/Akira%20Abe", "affiliation": { "@type": "Organization", "name": "Department of Molecular Science of Bacteria, Tokyo University of Agriculture, Tokyo, Japan. Electronic address: aabe@umich.edu." } }, { "@type": "Person", "name": "Shulin Hou", "url": "https://questionsmedicales.fr/author/Shulin%20Hou", "affiliation": { "@type": "Organization", "name": "Department of Nuclear Medicine, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China." } }, { "@type": "Person", "name": "Junping Bai", "url": "https://questionsmedicales.fr/author/Junping%20Bai", "affiliation": { "@type": "Organization", "name": "Key Laboratory of Coal Environmental Pathogenicity and Prevention (Shanxi Medical University), Ministry of Education, Taiyuan, Shanxi, China." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "A harmonized protocol for an international multicenter prospective study of nanotechnology workers: the NanoExplore cohort.", "datePublished": "2023-03-16", "url": "https://questionsmedicales.fr/article/36927342", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/17435390.2023.2180220" } }, { "@type": "ScholarlyArticle", "name": "Optimal surgical management of duodenal fistula in Crohn's disease: a Korean multicenter cohort study.", "datePublished": "2023-04-19", "url": "https://questionsmedicales.fr/article/37074597", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00384-023-04387-9" } }, { "@type": "ScholarlyArticle", "name": "Outcomes of invasive melanoma of the head and neck treated with Mohs micrographic surgery - A multicenter study.", "datePublished": "2023-01-13", "url": "https://questionsmedicales.fr/article/36642331", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jaad.2022.12.038" } }, { "@type": "ScholarlyArticle", "name": "Increased risk of severe COVID-19 in pregnancy in a multicenter propensity score-matched study.", "datePublished": "2023-08-21", "url": "https://questionsmedicales.fr/article/37596826", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1515/jpm-2023-0068" } }, { "@type": "ScholarlyArticle", "name": "Submandibular gland involvement in oral cavity squamous cell carcinoma: a retrospective multicenter study.", "datePublished": "2023-06-06", "url": "https://questionsmedicales.fr/article/37280380", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00405-023-08007-8" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Actions chimiques et utilisations", "item": "https://questionsmedicales.fr/mesh/D020164" }, { "@type": "ListItem", "position": 3, "name": "Actions pharmacologiques", "item": "https://questionsmedicales.fr/mesh/D020228" }, { "@type": "ListItem", "position": 4, "name": "Mécanismes moléculaires de l'action pharmacologique", "item": "https://questionsmedicales.fr/mesh/D045504" }, { "@type": "ListItem", "position": 5, "name": "Antienzymes", "item": "https://questionsmedicales.fr/mesh/D004791" }, { "@type": "ListItem", "position": 6, "name": "Inhibiteurs de la phospholipase A2", "item": "https://questionsmedicales.fr/mesh/D064801" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Inhibiteurs de la phospholipase A2 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Inhibiteurs de la phospholipase A2", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-06", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Inhibiteurs de la phospholipase A2", "description": "Comment diagnostiquer une inhibition de la phospholipase A2 ?\nQuels tests sont utilisés pour évaluer l'inhibition ?\nY a-t-il des marqueurs spécifiques pour l'inhibition ?\nL'imagerie est-elle utile dans ce diagnostic ?\nQuels symptômes peuvent indiquer une inhibition ?", "url": "https://questionsmedicales.fr/mesh/D064801?mesh_terms=Multicenter+Studies+as+Topic&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Inhibiteurs de la phospholipase A2", "description": "Quels sont les symptômes d'une inhibition de la phospholipase A2 ?\nL'inhibition provoque-t-elle des douleurs articulaires ?\nY a-t-il des symptômes digestifs associés ?\nLes symptômes varient-ils selon les individus ?\nPeut-on observer des symptômes cutanés ?", "url": "https://questionsmedicales.fr/mesh/D064801?mesh_terms=Multicenter+Studies+as+Topic&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Inhibiteurs de la phospholipase A2", "description": "Comment prévenir l'inhibition de la phospholipase A2 ?\nLes exercices physiques aident-ils à prévenir l'inhibition ?\nY a-t-il des habitudes à éviter ?\nLes compléments alimentaires sont-ils utiles ?\nLa gestion du stress peut-elle aider ?", "url": "https://questionsmedicales.fr/mesh/D064801?mesh_terms=Multicenter+Studies+as+Topic&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Inhibiteurs de la phospholipase A2", "description": "Quels traitements existent pour inhiber la phospholipase A2 ?\nLes corticostéroïdes sont-ils efficaces ?\nY a-t-il des traitements naturels disponibles ?\nComment les inhibiteurs spécifiques sont-ils administrés ?\nLes traitements nécessitent-ils un suivi médical ?", "url": "https://questionsmedicales.fr/mesh/D064801?mesh_terms=Multicenter+Studies+as+Topic&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Inhibiteurs de la phospholipase A2", "description": "Quelles complications peuvent survenir avec l'inhibition ?\nL'inhibition peut-elle entraîner des maladies chroniques ?\nY a-t-il des risques d'allergies ?\nLes complications sont-elles réversibles ?\nComment gérer les complications liées à l'inhibition ?", "url": "https://questionsmedicales.fr/mesh/D064801?mesh_terms=Multicenter+Studies+as+Topic&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Inhibiteurs de la phospholipase A2", "description": "Quels sont les facteurs de risque d'inhibition ?\nL'obésité est-elle un facteur de risque ?\nLe stress chronique influence-t-il l'inhibition ?\nLes antécédents familiaux jouent-ils un rôle ?\nL'âge est-il un facteur de risque ?", "url": "https://questionsmedicales.fr/mesh/D064801?mesh_terms=Multicenter+Studies+as+Topic&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une inhibition de la phospholipase A2 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests biochimiques mesurant l'activité de la phospholipase A2." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'inhibition ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests enzymatiques et des dosages d'acides gras peuvent être utilisés." } }, { "@type": "Question", "name": "Y a-t-il des marqueurs spécifiques pour l'inhibition ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des biomarqueurs comme les cytokines peuvent indiquer une inhibition de l'enzyme." } }, { "@type": "Question", "name": "L'imagerie est-elle utile dans ce diagnostic ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'imagerie n'est généralement pas utilisée pour diagnostiquer l'inhibition de la phospholipase A2." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer une inhibition ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes inflammatoires comme la douleur ou le gonflement peuvent survenir." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une inhibition de la phospholipase A2 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent douleur, inflammation et troubles métaboliques." } }, { "@type": "Question", "name": "L'inhibition provoque-t-elle des douleurs articulaires ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'inhibition peut entraîner des douleurs articulaires dues à l'inflammation." } }, { "@type": "Question", "name": "Y a-t-il des symptômes digestifs associés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles digestifs peuvent survenir, mais ce n'est pas systématique." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon les individus ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier en fonction de la sensibilité individuelle." } }, { "@type": "Question", "name": "Peut-on observer des symptômes cutanés ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des éruptions cutanées peuvent apparaître en raison de l'inflammation." } }, { "@type": "Question", "name": "Comment prévenir l'inhibition de la phospholipase A2 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée et un mode de vie sain peuvent aider à prévenir l'inhibition." } }, { "@type": "Question", "name": "Les exercices physiques aident-ils à prévenir l'inhibition ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier peut réduire l'inflammation et améliorer la santé globale." } }, { "@type": "Question", "name": "Y a-t-il des habitudes à éviter ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Éviter le tabac et l'alcool peut réduire le risque d'inhibition de l'enzyme." } }, { "@type": "Question", "name": "Les compléments alimentaires sont-ils utiles ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Certains compléments peuvent avoir des effets anti-inflammatoires, mais prudence." } }, { "@type": "Question", "name": "La gestion du stress peut-elle aider ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la gestion du stress peut réduire l'inflammation et améliorer la santé." } }, { "@type": "Question", "name": "Quels traitements existent pour inhiber la phospholipase A2 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments anti-inflammatoires et des inhibiteurs spécifiques sont utilisés." } }, { "@type": "Question", "name": "Les corticostéroïdes sont-ils efficaces ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les corticostéroïdes peuvent réduire l'inflammation liée à l'inhibition." } }, { "@type": "Question", "name": "Y a-t-il des traitements naturels disponibles ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Certaines plantes médicinales peuvent avoir des effets inhibiteurs, mais peu prouvés." } }, { "@type": "Question", "name": "Comment les inhibiteurs spécifiques sont-ils administrés ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent être administrés par voie orale ou injectable selon le médicament." } }, { "@type": "Question", "name": "Les traitements nécessitent-ils un suivi médical ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un suivi est essentiel pour ajuster le traitement et surveiller les effets." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec l'inhibition ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme des infections ou des troubles métaboliques peuvent survenir." } }, { "@type": "Question", "name": "L'inhibition peut-elle entraîner des maladies chroniques ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une inhibition prolongée peut contribuer à des maladies inflammatoires chroniques." } }, { "@type": "Question", "name": "Y a-t-il des risques d'allergies ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des réactions allergiques peuvent survenir avec certains inhibiteurs de l'enzyme." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être réversibles avec un traitement approprié." } }, { "@type": "Question", "name": "Comment gérer les complications liées à l'inhibition ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Un suivi médical régulier et un ajustement du traitement sont essentiels." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque d'inhibition ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'alimentation, le mode de vie et des prédispositions génétiques." } }, { "@type": "Question", "name": "L'obésité est-elle un facteur de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'obésité peut augmenter le risque d'inhibition de la phospholipase A2." } }, { "@type": "Question", "name": "Le stress chronique influence-t-il l'inhibition ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut exacerber l'inflammation et l'inhibition." } }, { "@type": "Question", "name": "Les antécédents familiaux jouent-ils un rôle ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de maladies inflammatoires peuvent augmenter le risque." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque d'inhibition peut augmenter avec l'âge en raison de l'inflammation." } } ] } ] }

Sources (10000 au total)

Optimal surgical management of duodenal fistula in Crohn's disease: a Korean multicenter cohort study.

Duodenal fistula in Crohn's disease (CDF) is a rare condition with an unclear optimal surgical management approach. We reviewed a Korean multicenter cohort of CDF surgery cases and assessed their peri... The medical records of patients who underwent CD surgery between January 2006 and December 2021 from three tertiary medical centers were retrospectively reviewed. Only CDF cases were included in this ... Among the initial population of 2149 patients who underwent surgery for CD, 23 cases (1.1%) had a CDF operation. Fourteen of these patients (60.9%) had a history of previous abdominal surgery, and 7 h... Optimal perioperative conditioning of patients receiving a primary repair of a fistula and resection of the original diseased bowel can successfully cure CDF. Along with primary repair of the duodenum...

Outcomes of invasive melanoma of the head and neck treated with Mohs micrographic surgery - A multicenter study.

There are no randomized controlled trials to guide surgical margins for invasive head and neck (H&N) melanoma using conventional excision. Mohs micrographic surgery (MMS) has shown improved local recu... Determine local recurrence (LR), nodal recurrence, and distant recurrence rates, and disease specific survival for invasive melanoma of the H&N treated with MMS.... A retrospective multicenter study of 785 cases of invasive H&N melanoma treated with MMS using frozen sections with melanoma antigen recognized by T-cells 1 immunohistochemical staining was performed ... 785 melanomas (thickness: 0.3 mm-8.5 mm) were treated with MMS. LR, nodal recurrence, and distant recurrence rates were 0.51% (4/785), 1.0% (8/785), and 1.1% (9/785) respectively. For T1, T2, T3, and ... A nonrandomized retrospective study.... MMS achieves significant improvements in LR compared to a meta-analysis of historical cohorts of patients treated with conventional excision. MMS should be considered an important surgical option for ...

Increased risk of severe COVID-19 in pregnancy in a multicenter propensity score-matched study.

To explore the association between COVID-19 severity and pregnancy using measures such as COVID-19 ordinal scale severity score, hospitalization, intensive care unit (ICU) admission, oxygen supplement... We conducted a retrospective, multicenter cohort study to understand the association between COVID-19 severity and pregnancy. We reviewed consecutive charts of adult females, ages 18-45, with laborato... A higher proportion of pregnant women had moderate to severe COVID-19 disease at the nadir of the clinical course than non-pregnant women (25 vs. 16.1 %, p=0.04, respectively). There was a higher rate... In our propensity score-matched study, COVID-19 in pregnancy is associated with an increased risk of disease severity and pregnancy complications....

Submandibular gland involvement in oral cavity squamous cell carcinoma: a retrospective multicenter study.

The submandibular gland (SMG) is routinely excised during neck dissection. Given the importance of the SMG in saliva production, it is important to understand its involvement rate by cancer tissue and... Retrospective data were collected from five academic centers in Europe. The study involved adult patients affected by primary oral cavity carcinoma (OCC) undergoing tumor excision and neck dissection.... A total of 642 patients were enrolled. The SMG involvement rate was 12/642 (1.9%; 95% CI 1.0-3.2) when considered per patient, and 12/852 (1.4%; 95% CI 0.6-2.1) when considered per gland. All the glan... The incidence of SMG involvement in primary OCC is rare. Therefore, exploring gland preservation as an option in selected cases would be reasonable. Future prospective studies are needed to investigat...

A prospective randomized multicenter trial for lymphadenectomy in early-stage ovarian cancer: LOVE study.

The Lymphadenectomy in Ovarian Neoplasms (LION) study revealed that systemic lymphadenectomy did not bring survival benefit for advanced ovarian cancer patients with clinically normal lymph nodes and ... We designed the LOVE study, a multicenter, randomized controlled, phase III trial to compare the efficacy and safety of comprehensive staging surgery with or without lymphadenectomy in stages IA-IIB E... ClinicalTrials.gov Identifier: NCT04710797....

Secondary Tumors Arising from Nevus Sebaceus: A Multicenter Collaborative Study and Literature Review.

Although various benign and malignant tumors can arise in nevus sebaceus (NS), the demographic and clinicopathological features of the secondary tumors vary among different published reports. The aim ... A multicenter study was performed by reviewing patients diagnosed with NS from the Dermatology Department of the First Affiliated Hospital of Chongqing Medical University and Qijiang Hospital of the F... We retrospectively analyzed the literature on tumors secondary to NS published since 2000, with a total of 443 cases, and carefully studied cases of tumors arising in NS from multiple centers since 20... The present study is the largest analysis of tumors secondary to NS. Racial differences were seen in secondary tumors to NS and may contribute to healthcare disparities between races....

Acupuncture as adjunctive therapy for patients with AECOPD: study protocol for a multicenter, randomized controlled trial.

The acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is a common respiratory disease among older adults, which imposes a significant burden on individuals and society and poses a m... This study proposes a prospective, multicenter randomized controlled trial that will comprise four groups, including two acupuncture treatment groups, one sham acupuncture group, and one basic treatme... Ethical approval was obtained from the Sichuan Regional Ethics Review of Committee on Traditional Chinese Medicine (Approval ID: 2022KL-068). The results of this study will be distributed through peer...

A critical review of "uterine leiomyoma" with subsequent recurrence or metastasis: A multicenter study of 62 cases.

Histopathologic diagnosis of a subset of uterine smooth muscle tumors is challenging. We report a critical review regarding the clinicopathological point of view of 62 cases of subsequently recurred o... Medical records and glass slides of 62 cases of uterine smooth muscle tumor diagnosed as leiomyoma, which subsequently recurred or metastasized, were critically reviewed by pathologists specializing i... In 47 (75.8%) of 62 cases, the diagnosis of leiomyoma was confirmed, including 11 intravascular leiomyomatosis (IVL) and benign metastasizing leiomyoma (BML). In 29 cases (46.8%) laparoscopic surgery ... The recurrence or metastasis in cases of "leiomyoma" is attributed to iatrogenic or under-evaluation of primary tumors, although a subset of cases is a rare example of biological progression....

The efficacy of nalmefene on anesthetic recovery of patients: a study protocol for a multicenter randomized controlled trial.

So far, the recovery quality after general anesthesia is still unsatisfied. Nalmefene is a drug to treat opioid overdose and reverse opioid actions. We aim to investigate the efficacy of nalmefene on ... It is a prospective, placebo-controlled, two-arm parallel groups, multicentre, double-blind, randomized (PPPMDR) clinical trial. The participants (n = 520) will be randomly assigned into two groups. E... This trial aims to study whether small dose of nalmefene can shorten the time from the end of surgery to Aldrete score ≥ 9 and improve opioid-induced side effects.This trial focuses on providing the r... This clinical trial has been approved and supported by the ethics committee of the Renji Hospital, Shanghai Jiaotong University, School of Medicine (KY2020-150); Shanghai Tongren Hospital (2021-030-01... ClinicalTrials.gov, NCT04713358, Registered on September 23, 2021....